We only take engagements we've already confirmed we can deliver.
Every study that comes through Clinical Enroll first goes through a protocol feasibility evaluation. If the math doesn't support a guarantee, we say so before any agreement is signed.
Check if your study qualifiesFour out of five clinical trials miss their enrollment timelines. That statistic is well-documented across the industry. What's less discussed is why: the dominant vendor model creates no accountability for outcome.
Traditional patient recruitment agencies bill for effort. Impressions delivered. Clicks generated. Media spend placed. These are activity metrics, and activity metrics measure what a vendor did, not what your study needed. When a campaign underperforms, the vendor invoices on time, files a case study about reach, and moves on. Your site absorbs the gap in enrollment and the downstream pressure on your sponsor relationship.
The coordinator burden problem compounds this. When a recruitment vendor sends unqualified referrals, patients who have not been evaluated against inclusion/exclusion criteria, your site coordinators carry the screening load. A coordinator reviewing forty referrals to find two eligible patients isn't a workflow problem. It's a vendor accountability problem. Coordinator burnout at high-volume sites tracks directly to low-quality referral pipelines.
Paying for effort while the vendor absorbs none of the outcome risk is not a performance standard. When your study timeline determines protocol viability, sponsor confidence, and site revenue, activity-based billing is a liability transfer from the vendor to you.
Four steps. One accountable outcome.
Protocol Feasibility Evaluation
Before Clinical Enroll commits to any engagement, we evaluate whether the study is one we can actually deliver on. If your study qualifies, we say so in writing. If it doesn't, we tell you why, at no cost, before you spend anything.
What we evaluate:
- Patient pool size. Is there a sufficient concentration of condition-matched patients within the geographic reach of your site? We require a minimum ratio of reachable, condition-qualified patients in the addressable market for every one enrollment target. A study targeting 4 randomized patients requires a meaningful identifiable patient population in market before we will commit.
- Eligibility criteria complexity. Studies with narrow inclusion windows (tight age bands, specific biomarker requirements, prior treatment restrictions) reduce the qualified patient pool proportionally. We model this against available data before proceeding.
- Site panel alignment. Does your site have the infrastructure, staffing, and visit schedule to handle the referral volume the campaign will generate? A guarantee that overwhelms a site's capacity to screen is not useful. We evaluate throughput before building campaign volume targets.
- Enrollment target math. We reverse-engineer the campaign structure from your randomization goal, not from a standard package. If the math doesn't produce a defensible path to your target, we do not proceed.
If a study does not qualify, we say so clearly and explain why. There is no penalty for the evaluation. It is free.
IRB-Ready Campaign Development
Once feasibility is confirmed, we build the campaign. Every element is developed for IRB review prior to deployment.
Clinical Enroll campaigns are developed in accordance with FDA guidance on clinical trial advertising. All creative assets, ad copy, imagery, landing page language, and pre-screening questionnaires are submitted through the site's existing IRB process. We do not deploy before IRB approval is documented.
Channel strategy is built for condition-specific patient audiences. The majority of campaigns use digital channels (Meta and Google) because they allow precise geographic and demographic targeting at the scope of the study site. For studies where community-level outreach improves reach, we layer in supplemental channels.
Every campaign includes a structured pre-screening layer before any referral reaches your coordinator. Patients respond to a condition-specific questionnaire that evaluates the key inclusion/exclusion criteria. This is not a generic interest form. It is a protocol-aligned screen.
Pre-Screened Patient Referrals
What your coordinator receives is not a lead list. It is a referral packet: a patient who has completed a protocol-specific questionnaire aligned to the study's inclusion/exclusion criteria. Patients who do not meet the criteria threshold are not referred.
What arrives in your portal: a patient who has confirmed they meet the primary eligibility conditions, understands the general nature of the study, and has expressed intent to participate. Your coordinator's job is to conduct the formal informed consent screening, not to filter a raw lead pool.
Optional secondary screening (via SMS or AI-assisted call) is available for studies where an additional qualification step before coordinator contact reduces screening burden further.
Enrollment Delivered, or Refunded
The contractual commitment is to randomization. Not to impressions, clicks, referrals, or screened patients. Your enrollment target, as defined in the engagement agreement, is the performance standard.
For qualifying studies: if we miss the contracted enrollment target, we run a second campaign at no charge. If the re-run also falls short, you receive a full refund. No partial credits. No retained fees.
Timeline: Feasibility assessment is completed within 24-48 hours. Campaign buildout (including IRB submission materials) typically takes 3-5 weeks. Active campaigns run 6-8 weeks on average, calibrated to your enrollment target and randomization timeline. All timelines are built into the engagement agreement at the outset.
Common questions about the model.
Find out if your study qualifies.
Submit your NCT ID for a free feasibility assessment. No call required to get your answer.
All campaigns developed for IRB review and deployed in accordance with FDA guidance on clinical trial advertising.